Key result
Indian RAAS-acting antihypertensives exhibit wide brand cost disparities, with price variations reaching ~7.8-fold.
Why the study?
Multiple brands of antihypertensive drugs are available in the Indian market with huge price variations, motivating an assessment of percentage cost variation and cost ratio among drugs acting through renin angiotensin aldosterone axis modulation.
Wide price variation among RAAS antihypertensives warrants cost awareness in prescribing; leaves open impact on adherence and outcomes.
Background: Several brands of antihypertensive drugs are available in the Indian market with huge price variations. This study was undertaken to find out the percentage cost variation and cost ratio of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation.Methods: Costs of different brands of renin angiotensin aldosterone axis modulatory drugs with antihypertensive action for the same dosage form and strength were found out using current index of medical specialties-134, July-October 2016. The maximum and minimum price of different brands of each drug was noted. Data was entered in Microsoft excel 2010. Percentage cost variation and cost ratio was calculated for each drug.Results: 16 antihypertensive drugs were analysed. Most of them were tablets. Ramipril and Valsartan were available as capsules also. Among tablets, percentage cost variation was highest for Atenolol 12.5 mg (683.93%) and least for Bisoprolol 2.5 mg (3.6538%). Valsartan capsules (160 mg) had no difference in the costs between the available 2 brands. Cost ratio ranged from 1.04 to 7.84 among the tablet form of drugs.Conclusions: There is a huge difference in the cost of antihypertensive drugs manufactured by different companies in the same strength and dosage form. To promote rational drug use and cost effective therapy, it is essential to create an awareness among clinicians regarding the availability of multiple brands for these drugs and the discrepancies in their costs.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2017) studied Hypertension. Antihypertensive drugs modulating the renin-angiotensin-aldosterone axis (ACE inhibitors, ARBs, beta-blockers, alpha methyldopa) vs. Different commercial brands of the same drug, dosage form, and strength was evaluated on Percentage cost variation and cost ratio across brands. Antihypertensive drugs acting on the renin-angiotensin-aldosterone axis in India showed percentage cost variations from 0% (valsartan 160 mg) to 683.93% (atenolol 12.5 mg), with cost ratios up to 7.84.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: